Xeris Biopharma Holdings, Inc. (XERS) stock
XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.80+0.10 (+0.60%)
Close on Nov 17, 2026Market cap $3.06BP/E –Yield –
Xeris Biopharma enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Xeris Biopharma's enterprise value was $3.00B on Nov 11, 2026, against $1.32B a year earlier. Over the last 5 years it ranged from $6.24M to $3.00B, with a median of $346.90M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.00B | +110.1% |
| 2025 | Dec 31, 2025 | $1.43B | +216.6% |
| 2024 | Dec 31, 2024 | $450.78M | +74.4% |
| 2023 | Dec 29, 2023 | $258.48M | +195.8% |
| 2022 | Dec 30, 2022 | $87.40M | -14.2% |
| 2021 | Dec 31, 2021 | $101.86M | – |
See a number that looks wrong?